Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance

Coherus BioSciences, Inc., a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer, received clearance from the Committee on Foreign Investment in the United States (CFIUS) in connection with the divestiture of its UDENYCA franchise to Intas Pharmaceuticals. CFIUS concluded that there were no unresolved national security issues with respect to the transaction.

Latham & Watkins LLP represented Coherus BioSciences in the transaction. The CFIUS team was led by Washington, D.C. partner Les Carnegie and Washington, D.C. counsel Catherine Hein, with associate Asia Cadet. The M&A team was led by Bay Area partners Josh Dubofsky and Benjamin Potter and counsel Danny Nordstrom, with associates Avery Brust, Rachelle Polsky, and Tim Plummer.